# Pathology Watch

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathology-watch

- Industry: Software
- Headquarters: Murray, US
- Website: www.pathologywatch.com
- Total disclosed funding: $31M
- Latest round: Series B (Dec 29, 2021)
- Investors on record: 12

## About

Pathology Watch Inc. is a US-based company that specializes in digital dermatopathology, enhancing the efficiency and accuracy of dermatological diagnostics through innovative technologies and streamlined workflows.Founded in 2018 in Murray, US, Pathology Watch Inc. provides advanced digital pathology solutions for dermatologists and pathologists. The company secured a total of USD 150.00 mn in funding through multiple rounds, with the latest being a TRADE SALE to Sonic Healthcare Limited on November 15, 2023. Founders Gregory Osmond and Michael Torno have a background in healthcare technology, contributing to the firm’s strategic direction and growth.PathologyWatch offers digital dermatopathology services that include a comprehensive electronic medical record (EMR) interface, facilitating enhanced specimen management and reporting for healthcare providers. Their services grant dermatologists and pathologists access to high-quality images and academic-level interpretations, ensuring swift and informed patient care decisions. The company's solutions primarily target dermatologists, dermatopathologists, and clinics throughout the United States, aiming to increase operational efficiency and improve patient outcomes.PathologyWatch operates on a business-to-business model, generating revenue from dermatology practices and healthcare providers through subscription-based access to their digital pathology platform. Clients contract services to send specimens for analysis, receiving detailed reports within 24-48 hours. The pricing structure is designed to ensure affordability while reflecting the value of services, fostering repeat business and partnerships with dermatological practices.With the recent acquisition by Sonic Healthcare Limited, Pathology Watch plans to enhance its digital pathology offerings and optimize laboratory operations. The company aims to expand its dermatopathology services and integrate AI tools from Franklin.ai, focusing on the development of AI-driven melanoma prognostics. Future initiatives will likely include launching new products and entering additional markets, leveraging the USD 130 mn from the acquisition to support these growth strategies.

## Funding rounds

- Series B, Dec 29, 2021, $22M — Rock Creek Capital, Blueprint Health, Gaingels, Spark Growth Ventures, Ceros Capital Markets, Blackbrook Management Group, SpringTide Capital Management
- Series A, Dec 16, 2020, $2M — BioVentures Investors, Sky Ventures Group, Beni Venture Capital, Lateral Capital Management, Harmonix
- Series A, Apr 28, 2020, $4.3M — Rock Creek Capital, SpringTide Capital Management
- Seed, Apr 23, 2019, $2.3M — SpringTide Capital Management

## Investors

- SpringTide Capital Management (https://capitalatlas.ai/funds/springtide-capital-management) — Seed, Series A, Series B
- Rock Creek Capital (https://capitalatlas.ai/funds/rock-creek-capital) — Series A, Series B
- BioVentures Investors (https://capitalatlas.ai/funds/bioventures-investors) — Series A
- Sky Ventures Group (https://capitalatlas.ai/funds/sky-ventures-group) — Series A
- Beni Venture Capital (https://capitalatlas.ai/funds/beni-venture-capital) — Series A
- Lateral Capital Management (https://capitalatlas.ai/funds/lateral-capital-management) — Series A
- Harmonix — Series A
- Blueprint Health — Series B
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B
- Spark Growth Ventures (https://capitalatlas.ai/funds/spark-growth-ventures) — Series B
- Ceros Capital Markets (https://capitalatlas.ai/funds/ceros-capital-markets) — Series B
- Blackbrook Management Group (https://capitalatlas.ai/funds/blackbrook-management-group) — Series B